Citations

Showing 10 of 108104 citations.

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
Arlt, Weibke, Decoudier, B., Lasolle, Hélène , Quinkler, M., Fragoso, Maria Candida Barisson Villares , Bourdeau, Isabelle , Baudin, Éric , Berruti, Alfredo , Faßnacht, Martin , Libé, Rossella , Lacroix, André , Kaštelan, Darko , Haak, Harm Reinout , Decoudier, B., Bancos, Irina , Canu, Letizia , Puglisi, Soraya , Berchialla, Paola , Beuschlein, Felix , Bertherat, Jérôme , Terzolo, Massimo

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 1-1

10.1200/jco.2022.40.6_suppl.001 Get It

1 Background: The ESE-ENSAT guidelines on ACC management suggest adjuvant mitotane for patients at high risk of recurrence. This indication has limited evidence base, lacking results from randomized controlled trials. No suggestion for or against adjuvant mitotane in low-risk patients was given, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in patients at low-intermediate risk of recurrence. Methods: The main inclusion criteria were: stage I-III ACC, R0 surgery, and Ki-67 ≤10%. Patients were randomly assigned 1:1 to adjuvant mitotane or observation. The primary endpoint of the study was RFS. Patients who refused randomization were eligible for the ADIUVO OBSERVATIONAL study. In this prospective, observational study, patients were managed as in ADIUVO except for randomization. A total of 91 patients were enrolled in ADIUVO, 45 in the mitotane and 46 in the observation arm. Baseline characteristics of patients were perfectly matched between the 2 arms: median age, 51 vs. 50.5 years; female, 73% vs. 67%; stage I, 20% vs. 26%; stage II, 67% vs. 63%, stage III, 13% vs. 11%; ACC secretion 44% vs. 36%; Weiss 5 vs. 5; respectively. In ADIUVO OBSERVATIONAL, 42 patients were treated with mitotane and 53 were untreated. Baseline characteristics of patients were matched between the 2 groups and with mitotane and observation groups in ADIUVO. Thus, the ADIUVO OBSERVATIONAL cohort was analyzed in parallel to deal with the lower than expected recruitment in ADIUVO. Results: In the ADIUVO study, recurrences were 8 in the MIT and 11 in the OBS arm, while deaths were 2 and 5, respectively. RFS and overall survival (OS) did not significantly differ between the 2 arms. In the OBS arm, the HR for recurrence was 1.321 (95%CI, 0.55-3.32, p = 0.54) and HR for death 2.171 (95%CI, 0.52-12.12, p = 0.29). The survival analysis in the ADIUVO OBSERVATIONAL study confirmed that of ADIUVO. Given the outcome of both studies, the NNT is 55. Conclusions: ACC patients at low-intermediate risk of recurrence after surgery are a minority; however, they show a far better prognosis than expected (5-yr RFS is 75%) and do not benefit significantly from adjuvant mitotane. The results of the ADIUVO study do not support routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This is an important step toward personalization of ACC care. Clinical trial information: NCT00777244.
Orbital and Periorbital Dysmorphology in Untreated Pfeiffer Syndrome
Lu, Xiaona, Forte, Antonio Jorge, Allam, Omar, Park, Kitae Eric, Wilson, Alexander, Alperovich, Michael, Steinbacher, Derek M., Tonello, Cristiano, Alonso, Nivaldo, Persing, John A., Forte, Antonio J. , Lu, Xiaona , Alonso, Nivaldo , Forte, Antonio Jorge , Lu, Xiaona, Allam, Omar, Park, Kitae Eric, Wilson, Alexander, Alperovich, Michael, Steinbacher, Derek M., Tonello, Cristiano, Persing, John A.

Mayo Clinic

Plastic & Reconstructive Surgery | February 16, 2022 | Volume: 149 | Issue: 4 | Pages: 731e-742e

10.1097/prs.0000000000008928 | PMID 35171849 Get It

Background: Visual impairment secondary to orbital and periorbital dysmorphology is frequent in Pfeiffer syndrome patients. The etiopathogenesis of this aberrancy, however, remains unclear. Methods: Untreated Pfeiffer syndrome patients (n = 31) and normal control subjects (n = 43) were compared. Craniometric and volumetric analyses related to the orbital and periorbital anatomy were performed using Materialise (Leuven, Belgium) software. Results: Overall, orbital cavity volume of Pfeiffer patients is reduced by 28 percent (p < 0.001), compared to normal, starting before 3 months of age (p = 0.004). Globe volume was diminished by 10 percent (p = 0.041) before 3 months of age, yet tended to catch up thereafter. However, the retrobulbar soft-tissue volume remained smaller beyond 1 year of age (17 percent, p = 0.003). Globe volume projection beyond the bony orbit increased in all observed ages (82 percent, p < 0.001). The volumes of sphenoid bone, maxilla, and mandible proportionately were restricted by 24 to 25 percent (p = 0.003 to 0.035) before 3 months of age. The volume of maxilla and mandible gradually approximate normal; however, the sphenoid bone volume in Pfeiffer patients remains less than normal (p = 0.002) into childhood. The anteroposterior length of both the zygoma and the maxilla was reduced by 14 percent (p < 0.001). Anterior positioning of the zygoma is less by 23 percent (p < 0.001) in Pfeiffer patients overall, with anterior positioning of maxilla reduced similarly by 23 percent (p < 0.001). Conclusions: Pfeiffer syndrome patients develop decreased retrobulbar soft-tissue and globe volume, along with a restricted orbital cavity volume in infancy. Significant hypoplasia of the sphenoid bone is associated with more severe central facial (maxilla) retrusion, compared to lateral facial structures (zygoma). CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.
PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
Sim, Hao‐Wen , Khasraw, Mustafa , Khasraw, Mustafa , Galanis, Evanthia

Mayo Clinic

Cancers | February 16, 2022 | Volume: 14 | Issue: 4 | Pages: 1003

10.3390/cancers14041003 | PMID 35205750 Get It

Gliomas are the most common malignant primary brain tumor in adults. Despite advances in multimodality therapy, incorporating surgery, radiotherapy, systemic therapy, tumor treating fields and supportive care, patient outcomes remain poor, especially in glioblastoma where median survival has remained static at around 15 months, for decades. Low-grade gliomas typically harbor isocitrate dehydrogenase (IDH) mutations, grow more slowly and confer a better prognosis than glioblastoma. However, nearly all gliomas eventually recur and progress in a way similar to glioblastoma. One of the novel therapies being developed in this area are poly(ADP-Ribose) polymerase (PARP) inhibitors. PARP inhibitors belong to a class of drugs that target DNA damage repair pathways. This leads to synthetic lethality of cancer cells with coexisting homologous recombination deficiency. PARP inhibitors may also potentiate the cytotoxic effects of radiotherapy and chemotherapy, and prime the tumor microenvironment for immunotherapy. In this review, we examine the rationale and clinical evidence for PARP inhibitors in glioma and suggest therapeutic opportunities.
Optimizing Nanopore Sequencing for Rapid Detection of Microbial Species and Antimicrobial Resistance in Patients at Risk of Surgical Site Infections
Whittle, Emma , Jeraldo, Patricio , Nelson, Heidi , Kendrick, Michael L. , Patel, Robin , Truty, Mark J. , Yonkus, Jennifer A. , Jeraldo, Patricio R , Alva-Ruiz, Roberto, Grys, Thomas E. , Patel, Robin , Alva‐Ruiz, Roberto , Chia, Nicholas

Mayo Clinic

mSphere | February 16, 2022 | Volume: 7 | Issue: 1 | Pages: No page available

10.1128/msphere.00964-21 | PMID 35171692 Get It

Surgical site infections (SSI) are a significant burden to patients and health care systems. They increase mortality rates, length of hospital stays, and associated health care costs.
Risk factors and long-term course of gastroesophageal reflux disease after peroral endoscopic myotomy: A large-scale multicenter cohort study in Japan
Shiwaku, Hironari , Sato, Hiroki , Shimamura, Yuto , Shiota, Junya , Ominami, Masaki , Sakae, Hiroyuki , Hata, Yoshitaka , Fukuda, Hisashi , Ogawa, Ryo , Tatsuta, Tetsuya , Yokomichi, Hiroshi , Inoue, Haruhiro , Sakae, Hiroyuki , Hata, Yoshitaka , Shimamura, Yuto , Abe, Hirofumi , Sato, Chiaki , Nakamura, Jun , Ikebuchi, Yuichiro , Hasegawa, Suguru

Mayo Clinic

Endoscopy | February 16, 2022 | Volume: 54 | Issue: 09 | Pages: 839-847

10.1055/a-1753-9801 | PMID 35172368 Get It

Abstract Background Gastroesophageal reflux disease (GERD) and reflux esophagitis remain problems after peroral endoscopic myotomy (POEM). This study aimed to elucidate the risk factors and long-term course of reflux esophagitis and symptomatic GERD after POEM. Methods This multicenter cohort study involved 14 high volume centers. Overall, 2905 patients with achalasia-related esophageal motility disorders treated with POEM were analyzed for reflux esophagitis, severe reflux esophagitis (Los Angeles classification C or D), and symptomatic GERD. Results Reflux esophagitis was diagnosed in 1886 patients (64.9 %). Age ≥ 65 years (risk ratio [RR] 0.85), male sex (RR 1.11), posterior myotomy (RR 1.12), esophageal myotomy > 10 cm (RR 1.12), and gastric myotomy > 2 cm (RR 1.17) were independently associated with reflux esophagitis. Severe reflux esophagitis was diagnosed in 219 patients (7.5 %). Age ≥ 65 years (RR 1.72), previous treatments (RR 2.21), Eckardt score ≥ 7 (RR 0.68), sigmoid-type achalasia (RR 1.40), and esophageal myotomy > 10 cm (RR 1.59) were factors associated with severe reflux esophagitis. Proton pump inhibitors (PPIs) were more effective for reflux esophagitis at 5-year follow-up (P = 0.03) than after 1 year (P = 0.08). Symptomatic GERD was present in 458 patients (15.9 %). Symptom duration ≥ 10 years (RR 1.28), achalasia diagnosis (RR 0.68), integrated relaxation pressure ≥ 26 (RR 0.60), and posterior myotomy (RR 0.80) were associated with symptomatic GERD. The incidence of symptomatic GERD was lower at 5-year follow-up compared with that after 1 year (P = 0.04), particularly in PPI users (P < 0.001). Conclusions The incidence of severe reflux esophagitis was low after POEM, but excessive myotomy for older patients with previous treatments should be avoided. Early phase symptomatic GERD is non-acid reflux dependent and the natural course is favorable, basically supporting conservative treatment.
Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence
Venkatramani, Vivek , Gonzalgo, Mark L. , Castle, Erik P., Svatek, Robert S. , Weizer, Alon Z. , Konety, Badrinath R. , Tollefson, Mathew, Krupski, Tracey L. , Smith, Norm D. , Shabsigh, Ahmad , Barocas, Daniel A. , Dash, Atreya , Parekh, Dipen J. , Reis, Isildinha Marques dos , Woods, Michael E. , Quek, Marcus Lee

Mayo Clinic

JAMA Network Open | February 16, 2022 | Volume: 5 | Issue: 2 | Pages: e2148329

10.1001/jamanetworkopen.2021.48329 | PMID 35171260 Get It

Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2
Vega, Rodolfo E. De la , Griensven, Martijn van , Zhang, Wen , Coenen, Michael J., Nagelli, Christopher V. , Panos, Joseph A. , Silva, Carlos Julio Peniche , Geiger, Johannes , Plank, Christian , Evans, Christopher H. , Balmayor, Elizabeth R. , De La Vega, Rodolfo E , van Griensven, Martijn , Peniche Silva, Carlos J , Balmayor, Elizabeth R

Mayo Clinic

Science Advances | February 16, 2022 | Volume: 8 | Issue: 7 | Pages: No page available

10.1126/sciadv.abl6242 | PMID 35171668 Get It

Large segmental osseous defects heal poorly. Recombinant, human bone morphogenetic protein-2 (rhBMP-2) is used clinically to promote bone healing, but it is applied at very high doses that cause adverse side effects and raise costs while providing only incremental benefit. We describe a previously unexplored, alternative approach to bone regeneration using chemically modified messenger RNA (cmRNA). An optimized cmRNA encoding BMP-2 was delivered to critical-sized femoral osteotomies in rats. The cmRNA remained orthotopically localized and generated BMP locally for several days. Defects healed at doses ≥25 μg of BMP-2 cmRNA. By 4 weeks, all animals treated with 50 μg of BMP-2 cmRNA had bridged bone defects without forming the massive callus seen with rhBMP-2. Moreover, such defects recovered normal mechanical strength quicker and initiated bone remodeling faster. cmRNA regenerated bone via endochondral ossification, whereas rhBMP-2 drove intramembranous osteogenesis; cmRNA provides an innovative, safe, and highly translatable technology for bone healing.
The Legacy of John W. Frymoyer, MD, FAAOS
Rose, Peter S., Rose, Peter S.

Mayo Clinic

Journal of the American Academy of Orthopaedic Surgeons | February 16, 2022 | Volume: 30 | Issue: 6 | Pages: 239-239

10.5435/jaaos-d-22-00017 | PMID 35981962 Get It

Does limited EMG denervation in early primary lateral sclerosis predict amyotrophic lateral sclerosis?
Hassan, Anhar , Hu, William T. , Josephs, Keith A. , Sorenson, Eric J. , Ahlskog, J. Eric , Mittal, Shivam Om , Hu, William T.

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | February 16, 2022 | Volume: 23 | Issue: 7-8 | Pages: 554-561

10.1080/21678421.2022.2039714 | PMID 35170382 Get It

Ten-Year Outcomes of Off-Pump vs On-Pump Coronary Artery Bypass Grafting in the Department of Veterans Affairs
Quin, Jacquelyn A. , Wagner, Todd H. , Hattler, Brack , Carr, Brendan M. , Collins, Joseph F. , Almassi, G. Hossein , Grover, Frederick L., Shroyer, A. Laurie

Mayo Clinic

JAMA Surgery | February 16, 2022 | Volume: 157 | Issue: 4 | Pages: 303

10.1001/jamasurg.2021.7578 | PMID 35171210 Get It